Actuate Therapeutics (ACTU) Registration filing summary

Company overview and business model

• Clinical-stage biopharma developing cancer therapies through GSK-3 inhibition; lead candidate elraglusib is an ATP-competitive small molecule licensed from the University of Illinois Chicago and Northwestern University.

• Elraglusib is being developed as an IV injection and oral tablet; over 500 patients have received IV elraglusib in Phase 1 and Phase 2 studies.

• Oral tablet Phase 1/2 study cleared by FDA after an April 2026 IND filing; initial goals are determining MTD and RP2D in adults with advanced, refractory cancers.

Financial performance and metrics

• As of June 30, 2026, cash and cash equivalents were $4.43 million and working capital was $0.94 million.

• No product-sales revenue since inception; significant operating losses and negative operating cash flows, with further losses expected as clinical development advances.

• June 30, 2026 net tangible book value was approximately $0.99 million, or $0.04 per share; adjusted value after the base offering was approximately $38.8 million, or $0.52 per share.

Use of proceeds and capital allocation

• Net proceeds are designated for working capital and general corporate purposes; no specific allocations are set, leaving management broad discretion over amounts and timing.

• Existing financing channels include a B. Riley equity facility with 3,364,407 shares of remaining capacity and an ATM facility with approximately $98.7 million of remaining capacity, both as of June 30, 2026.